Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 19741 AL 19755

Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease

Villain N, Fouquet M, Baron JC, Mézenge F, Landeau B, de La Sayette V, Viader F, Eustache F, Desgranges B, Chételat G.

Brain. 2010 Nov;133(11):3301-14. doi: 10.1093/brain/awq203. Epub 2010 Aug 5.

Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease

Manev H, Chen H, Dzitoyeva S, Manev R.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):315-9. doi: 10.1016/j.pnpbp.2010.07.032. Epub 2010 Aug 5.

Confirmation rate of blinded (99m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease

Schmidt D, Zimmermann R, Lewczuk P, Schaller G, Degirmenci U, Kreil S, Wiltfang J, Kuwert T, Kornhuber J, Weih M.

J Neural Transm (Vienna). 2010 Sep;117(9):1111-4. doi: 10.1007/s00702-010-0459-7. Epub 2010 Aug 7.

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Irwin N, Gault V, Flatt PR.

Expert Opin Investig Drugs. 2010 Sep;19(9):1039-48. doi: 10.1517/13543784.2010.513381.

The multifactorial nature of Alzheimer's disease and related therapeutic strategies

do Carmo Carreiras M, Marco-Contelles J.

Curr Pharm Des. 2010;16(25):2765. doi: 10.2174/138161210793176554.

Cell death targets and potential modulators in Alzheimer's disease

Castro RE, Santos MM, Glória PM, Ribeiro CJ, Ferreira DM, Xavier JM, Moreira R, Rodrigues CM.

Curr Pharm Des. 2010;16(25):2851-64. doi: 10.2174/138161210793176563.

Nitric oxide: target for therapeutic strategies in Alzheimer's disease

Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, Martinez-Murillo R.

Curr Pharm Des. 2010;16(25):2837-50. doi: 10.2174/138161210793176590.

Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease

Agostinho P, Cunha RA, Oliveira C.

Curr Pharm Des. 2010;16(25):2766-78. doi: 10.2174/138161210793176572.

Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis

Kawahara M.

Curr Pharm Des. 2010;16(25):2779-89. doi: 10.2174/138161210793176545.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. doi: 10.2174/138161210793176581.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents

Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ.

Curr Pharm Des. 2010;16(25):2818-36. doi: 10.2174/138161210793176536.

Review: omega-3 and memory function: to eat or not to eat

Itua I, Naderali EK.

Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):479-82. doi: 10.1177/1533317510376943. Epub 2010 Aug 11.

Inaccuracy in clinical trials: effects and methods to control inaccuracy

Kobak KA.

Curr Alzheimer Res. 2010 Nov;7(7):637-41. doi: 10.2174/156720510793499057.

Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease

Pflanzner T, Kuhlmann CR, Pietrzik CU.

Curr Alzheimer Res. 2010 Nov;7(7):578-90. doi: 10.2174/156720510793499066.

Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Becker RE, Greig NH.

Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias